Aptinyx (NASDAQ:APTX) Rating Lowered to Underweight at JPMorgan Chase & Co.

Aptinyx (NASDAQ:APTX) was downgraded by research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports.

A number of other equities analysts have also weighed in on the company. Zacks Investment Research upgraded Aptinyx from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Tuesday, July 16th. ValuEngine upgraded Aptinyx from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Svb Leerink began coverage on Aptinyx in a research note on Thursday, June 20th. They set an “outperform” rating and a $12.00 price objective for the company. Cowen restated a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Aptinyx in a research report on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $12.71.

NASDAQ APTX opened at $3.29 on Tuesday. The company’s 50-day moving average is $3.62. The stock has a market cap of $121.83 million, a price-to-earnings ratio of -1.25 and a beta of -0.03. Aptinyx has a fifty-two week low of $2.88 and a fifty-two week high of $32.25.



Aptinyx (NASDAQ:APTX) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.36) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.16. The business had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.95 million. Aptinyx had a negative return on equity of 38.42% and a negative net margin of 1,504.24%. Equities research analysts forecast that Aptinyx will post -2.15 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. A.R.T. Advisors LLC grew its position in shares of Aptinyx by 15.9% during the 2nd quarter. A.R.T. Advisors LLC now owns 27,000 shares of the company’s stock valued at $90,000 after acquiring an additional 3,695 shares during the period. Gabelli Funds LLC grew its position in shares of Aptinyx by 45.9% during the 2nd quarter. Gabelli Funds LLC now owns 15,901 shares of the company’s stock valued at $53,000 after acquiring an additional 5,000 shares during the period. Metropolitan Life Insurance Co. NY grew its position in shares of Aptinyx by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock valued at $120,000 after acquiring an additional 5,652 shares during the period. Bank of New York Mellon Corp grew its position in shares of Aptinyx by 30.6% during the 4th quarter. Bank of New York Mellon Corp now owns 43,887 shares of the company’s stock valued at $726,000 after acquiring an additional 10,284 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Aptinyx by 430.0% during the 4th quarter. Bank of America Corp DE now owns 13,213 shares of the company’s stock valued at $218,000 after acquiring an additional 10,720 shares during the period. Hedge funds and other institutional investors own 58.30% of the company’s stock.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Article: Federal Reserve

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.